Differential requirements for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice

Leukemia

Volumn 25, Issue 12, 2011, Pages 1857-1868

  Zhang, J ^a,b,b   Xiao, Y ^b   Guo, Y ^b,c   Breslin, P ^b,d   Zhang, S ^b   Wei, W ^b   Zhang, Z ^a,b  

^a SHANGHAI NORMAL UNIVERSITY   (China)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

c Myc; lymphadenopathy; lymphoma; MPD; Pten

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ACUTE LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; GRANULOCYTE; HEMATOPOIETIC SYSTEM; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MEGAKARYOCYTE; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE C MYC; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CELL COMMUNICATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; GRANULOCYTES; HEMATOLOGIC NEOPLASMS; INTEGRASES; MALE; MEGAKARYOCYTES; MICE; MICE, KNOCKOUT; MYELOPROLIFERATIVE DISORDERS; PROTO-ONCOGENE PROTEINS C-MYC; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 83555168276     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.220     Document Type: Article

References (55)

1. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8: 976-990.
2. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22: 2755-2766.
3. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 2002; 21: 3414-3421. (Pubitemid 34587713)
4. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006; 20: 2096-2109. (Pubitemid 44157460)
5. Fang ZH, Dong CL, Chen Z, Zhou B, Liu N, Lan HF et al. Transcriptional regulation of survivin by c-Myc in BCR/ABLtransformed cells: implications in antileukemic strategy. J Cell Mol Med 2009; 13: 2039-2052.
6. Schreiner S, Birke M, Garcia-Cuellar MP, Zilles O, Greil J, Slany RK. MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation. Cancer Res 2001; 61: 6480-6486. (Pubitemid 32783255)
7. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006; 16: 318-330. (Pubitemid 44311040)
8. Smith DP, Bath ML, Harris AW, Cory S. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC. Oncogene 2005; 24: 3544-3553. (Pubitemid 40756224)
9. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for highincidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988; 167: 353-371. (Pubitemid 18073641)
10. Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 2005; 106: 2452-2461. (Pubitemid 41510820)
11. Skoda RC, Tsai SF, Orkin SH, Leder P. Expression of c-MYC under the control of GATA-1 regulatory sequences causes erythroleukemia in transgenic mice. J Exp Med 1995; 181: 1603-1613.
12. Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 2008; 3: 611-624.
13. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Basecke J et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008; 22: 686-707. (Pubitemid 351565618)
14. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 2010; 115: 1406-1415.
15. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22: 708-722. (Pubitemid 351565619)
16. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 2010; 29: 1249-1259.
17. Bonnet M, Loosveld M, Montpellier B, Navarro JM, Quilichini B, Picard C et al. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood 2011; 117: 6650-6659.
18. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009; 114: 647-650.
19. Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, Ko YW et al. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol 2003; 122: 454-456. (Pubitemid 36951630)
20. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118: 3762-3774.
21. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007; 447: 966-971. (Pubitemid 46975753)
22. Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 2010; 116: 2513-2521.
23. Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric Tcell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia 2009; 23: 1417-1425.
24. Barata JT. The impact of PTEN regulation by CK2 on PI3Kdependent signaling and leukemia cell survival. Adv Enzyme Regul 2011; 51: 37-49.
25. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E et al. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 2011; 117: 3617-3628.
26. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000; 20: 5010-5018. (Pubitemid 30431555)
27. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross J et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006; 441: 518-522. (Pubitemid 44050154)
28. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441: 475-482. (Pubitemid 44050144)
29. Guo W, Lasky JL, Chang CJ, Mosessian S, Lewis X, Xiao Y et al. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 2008; 453: 529-533. (Pubitemid 351733319)
30. Xue L, Nolla H, Suzuki A, Mak TW, Winoto A. Normal development is an integral part of tumorigenesis in T cell-specific PTEN-deficient mice. Proc Natl Acad Sci USA 2008; 105: 2022-2027. (Pubitemid 351439458)
31. de Alboran IM, O'Hagan RC, Gartner F, Malynn B, Davidson L, Rickert R et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 2001; 14: 45-55. (Pubitemid 32144686)
32. Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001; 14: 523-534. (Pubitemid 32520864)
33. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995; 269: 1427-1429.
34. Novak A, Guo C, Yang W, Nagy A, Lobe CG. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis 2000; 28: 147-155.
35. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-841. (Pubitemid 37351467)
36. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten± mice. Science 1999; 285: 2122-2125. (Pubitemid 29451429)
37. Guo Y, Niu C, Breslin P, Tang M, Zhang S, Wei W et al. c-Mycmediated control of cell fate in megakaryocyte-erythrocyte progenitors. Blood 2009; 114: 2097-2106.
38. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001; 98: 11563-11568. (Pubitemid 32928768)
39. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009; 4: 127-150.
40. Knobbe CB, Lapin V, Suzuki A, Mak TW. The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Oncogene 2008; 27: 5398-5415.
41. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 409-414. (Pubitemid 36626987)
42. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12: 528-541. (Pubitemid 350199070)
43. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667. (Pubitemid 39063268)
44. Hu Y, Chen Y, Douglas L, Li S. Beta-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009; 23: 109-116.
45. Miyazaki T, Liu ZJ, Kawahara A, Minami Y, Yamada K, Tsujimoto Y et al. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 1995; 81: 223-231.
46. Waters CM, Littlewood TD, Hancock DC, Moore JP, Evan GI. cmyc protein expression in untransformed fibroblasts. Oncogene 1991; 6: 797-805. (Pubitemid 21924153)
47. Dose M, Khan I, Guo Z, Kovalovsky D, Krueger A, von Boehmer H et al. c-Myc mediates pre-TCR-induced proliferation but not developmental progression. Blood 2006; 108: 2669-2677.
48. Douglas NC, Jacobs H, Bothwell AL, Hayday AC. Defining the specific physiological requirements for c-Myc in T cell development. Nat Immunol 2001; 2: 307-315. (Pubitemid 33706341)
49. Dose M, Sleckman BP, Han J, Bredemeyer AL, Bendelac A, Gounari F. Intrathymic proliferation wave essential for Valpha14+ natural killer T cell development depends on c-Myc. Proc Natl Acad Sci USA 2009; 106: 8641-8646.
50. Mycko MP, Ferrero I, Wilson A, Jiang W, Bianchi T, Trumpp A et al. Selective requirement for c-Myc at an early stage of V(alpha)14i NKT cell development. J Immunol 2009; 182: 4641-4648.
51. Bianchi T, Gasser S, Trumpp A, MacDonald HR. c-Myc acts downstream of IL-15 in the regulation of memory CD8 T-cell homeostasis. Blood 2006; 107: 3992-3999. (Pubitemid 43726806)
52. Wanner M, Celebi JT, Peacocke M. Identification of a PTEN mutation in a family with Cowden syndrome and Bannayan-Zonana syndrome. J Am Acad Dermatol 2001; 44: 183-187. (Pubitemid 32172177)
53. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 64-67. (Pubitemid 27198157)
54. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-730. (Pubitemid 41117277)
55. He XC, Yin T, Grindley JC, Tian Q, Sato T, Tao WA et al. PTENdeficient intestinal stem cells initiate intestinal polyposis. Nat Genet 2007; 39: 189-198. (Pubitemid 46184349)